Compare Gitlab Inc (GTLB) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Invesco Ltd. — how do they compare? Gitlab Inc trades at $31.86 (market cap $5.54B), while Invesco Ltd. trades at $30.32 (market cap $13.43B). The key difference: Invesco Ltd. is far larger — about 2.4× Gitlab Inc's market cap, and Invesco Ltd. pays a 2.84% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | IVZ | |
|---|---|---|
Market Cap | $5.54B | $13.43B |
Sector | Technology | Financials |
52-Week High | $51.04 | $30.30 |
52-Week Low | $19.42 | $16.88 |
Enterprise Value | $4.29B | $23.68B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab trades at $31.50, down 4.49% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $759.25M in 2025, though net income remained negative at -$6.33M. Recent earnings beats and a strategic position in AI-driven DevSecOps, including a fourth consecutive Gartner Magic Quadrant leadership recognition (Business Wire, 2026-06-17), highlight growth potential despite profitability challenges.
The outlook balances strong revenue growth and market position against high valuation multiples and persistent losses. Analyst consensus targets $32.50, suggesting modest upside, but risks include execution on profitability and competitive pressures in the software sector. Cash flow trends show improvement projected for 2026, yet investor caution is warranted given the elevated P/E ratio of 521.22.
Invesco (IVZ) trades at $30.50, up 6.16% in the past 24 hours, with a bullish technical signal from moving averages. The company reported mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $6.38 billion in 2025, though net income remained negative at -$281.70 million. Analyst consensus is divided with 12 buys and 16 holds, targeting $30.50 on average. Recent news highlights dividend declarations and AUM growth to $2.47 trillion as of June 2026.
The outlook for IVZ is cautiously optimistic, supported by strong cash flow from operations and upward earnings revisions. Key risks include persistent negative profit margins and competitive pressures in asset management. Upside potential hinges on execution improvements and market sentiment shifts, with the current price near the consensus target suggesting limited near-term movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
